Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00421317
Recruitment Status : Terminated (Study stopped at the end of the first step)
First Posted : January 11, 2007
Last Update Posted : January 6, 2016
National Cancer Institute, France
Information provided by (Responsible Party):
Centre Oscar Lambret

Brief Summary:
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Imatinib Phase 2

Detailed Description:
Further study details as provided by Centre Oscar Lambret

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma
Study Start Date : December 2005
Actual Primary Completion Date : March 2007
Actual Study Completion Date : March 2007

Intervention Details:
  • Drug: Imatinib
    800 mg/day until disease progression or toxicity

Primary Outcome Measures :
  1. Progression-free rate at 3 months

Secondary Outcome Measures :
  1. Progression-free rate at 6 and 12 months
  2. Response rate according to RECIST criteria
  3. Toxicity
  4. Global survival,Progression-free survival
  5. Predictive genomic factors of response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic ocular melanoma
  • Age > or = 18 years old
  • Measurable metastases > or = 10 mm according to RECIST criteria
  • PS-WHO < or = 1 or IK > 70 percent
  • Normal hepatic function
  • PNN > 1500/mm3, platelets > or = 100 000/mm3
  • Contraception
  • Informed consent signed

Exclusion Criteria:

  • Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association)
  • Other evolutive neoplasic disease
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Somatic or psychiatric co-morbidity incompatible with the protocol
  • Leptomeningeal or cerebral metastatic dissemination
  • Pregnant or lactating woman
  • Other antitumoral treatment
  • Patient participating to another clinical trial with an experimental drug
  • Known hypersensitivity to Imatinib or one of its excipients
  • Resecable single metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00421317

Centre Francois Baclesse
Caen, France, 14076
Centre Jean Perrin
Clermont-Ferrand, France, 63011
Centre Georges-Francois Leclerc
Dijon, France, 21079
Centre Oscar Lambret
Lille, France, 59020
Centre Hospitalier Regional Universitaire
Lille, France, 59035
Centre Leon Berard
Lyon, France, 69373
Centre Val d'Aurelle Paul Lamarque
Montpellier, France, 34298
Institut Curie
Paris, France, 75248
Centre Paul Strauss
Strasbourg, France, 67065
Hopital Universitaire de Hautepierre
Strasbourg, France, 67098
Institut Claudius Regaud
Toulouse, France, 31052
Centre Gustave Roussy
Villejuif, France, 94805
Sponsors and Collaborators
Centre Oscar Lambret
National Cancer Institute, France
Principal Investigator: PENEL Nicolas, MD Centre Oscar Lambret

Responsible Party: Centre Oscar Lambret Identifier: NCT00421317     History of Changes
Other Study ID Numbers: O-Mel-Inib 0508
First Posted: January 11, 2007    Key Record Dates
Last Update Posted: January 6, 2016
Last Verified: January 2016

Keywords provided by Centre Oscar Lambret:
Ocular, Metastatic melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action